Hainan Shuangcheng Pharmaceuticals Co., Ltd. Class A

As of June 30, 2026, Hainan Shuangcheng Pharmaceuticals Co., Ltd. Class A carries a market capitalization of 3.92B, placing it among publicly traded companies globally. Its enterprise value stands at 4.09B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Hainan Shuangcheng Pharmaceuticals Co., Ltd. Class A has 414.69M shares outstanding.

As of June 30, 2026, Hainan Shuangcheng Pharmaceuticals Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 146.62. The price-to-sales ratio is 14.40, and the price-to-book ratio stands at 9.21.

As of June 30, 2026, Hainan Shuangcheng Pharmaceuticals Co., Ltd. Class A trades at an EV/EBITDA multiple of 262.33 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 15.00 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 262.33 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 4.09B versus a market cap of 3.92B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Hainan Shuangcheng Pharmaceuticals Co., Ltd. Class A maintains a current ratio of 0.62, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 46.50, indicating elevated leverage, while an interest coverage ratio of 1.64 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Hainan Shuangcheng Pharmaceuticals Co., Ltd. Class A posted a return on equity (ROE) of 6.61, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 3.40, measuring how efficiently the asset base is converted into earnings. The company generates approximately 493,142.82 in revenue per employee across its workforce of 552.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.61 indicates how many times Hainan Shuangcheng Pharmaceuticals Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Hainan Shuangcheng Pharmaceuticals Co., Ltd. Class A recorded an income tax benefit of -492,137.09 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 14.77M, leaving 26.77M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Hainan Shuangcheng Pharmaceuticals Co., Ltd. Class A's stock has gained approximately 18.41% over the past 52 weeks. The 50-day moving average sits at 9.26, while the 200-day moving average is 8.73.

Over the twelve months ended June 30, 2026, Hainan Shuangcheng Pharmaceuticals Co., Ltd. Class A generated 272.46M in revenue and converted that into 26.77M in net income, yielding earnings per share of 0.04. EBITDA reached 15.57M, while operating income came in at 33.77M.

As of June 30, 2026, Hainan Shuangcheng Pharmaceuticals Co., Ltd. Class A holds 40.33M in cash and equivalents against 199.69M in total debt, resulting in a net debt position of 22.78M. Total book value stands at 426.08M, with working capital of -118.81M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Hainan Shuangcheng Pharmaceuticals Co., Ltd. Class A posted a gross margin of 52.12, reflecting its pricing power and cost economics. The operating margin of 12.39 and net profit margin of 9.82 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Hainan Shuangcheng Pharmaceuticals Co., Ltd. Class A paid dividends of 0.02 per share. The dividend payout ratio of 165.52 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 0.83, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Hainan Shuangcheng Pharmaceuticals Co., Ltd. Class A shareholders.

Hainan Shuangcheng Pharmaceuticals Co., Ltd. Class A's most recent stock split took place on March 10, 2015 with a 2:3 split ratio.

As of June 30, 2026, Hainan Shuangcheng Pharmaceuticals Co., Ltd. Class A has an Altman Z-Score of 5.68, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.